Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open‐label study (SOAR‐KOBE Study)

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 (SGLT‐2) inhibitors improve blood glucose control, as well as reducing bodyweight by promoting urinary glucose excretion. The weight loss is less than expected from urinary glucose loss, however, likely because of an increase in food intake. To inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Miura, Hiroshi, Sakaguchi, Kazuhiko, Okada, Yuko, Yamada, Tomoko, Otowa‐Suematsu, Natsu, So, Anna, Komada, Hisako, Hirota, Yushi, Ohara, Takeshi, Kuroki, Yasuo, Hara, Kenta, Matsuda, Tomokazu, Kishi, Minoru, Takeda, Akihiko, Yokota, Kazuki, Tamori, Yoshikazu, Ogawa, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717805/
https://www.ncbi.nlm.nih.gov/pubmed/30688412
http://dx.doi.org/10.1111/jdi.13015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717805/
https://www.ncbi.nlm.nih.gov/pubmed/30688412
http://dx.doi.org/10.1111/jdi.13015

Ejemplares similares